AXIM Biotechnologies, Inc. (OTCMKTS:AXIM – Get Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 19,085 shares, a decline of 95.4% from the August 15th total of 417,214 shares. Based on an average daily volume of 731,294 shares, the short-interest ratio is presently 0.0 days.
AXIM Biotechnologies Price Performance
AXIM traded up $0.00 during trading on Thursday, reaching $0.00. 59,178 shares of the company were exchanged, compared to its average volume of 285,802. AXIM Biotechnologies has a 12-month low of $0.00 and a 12-month high of $0.03.
About AXIM Biotechnologies
AXIM Biotechnologies, Inc is a development-stage biotechnology company focused on the research, development and commercialization of cannabinoid-based technologies. The company’s primary objective is to advance formulations and delivery systems for cannabidiol (CBD) and other cannabinoids, targeting applications in nutraceuticals, skincare and medical devices. Through its proprietary encapsulation and atomization techniques, AXIM aims to enhance the bioavailability and stability of cannabinoid compounds for consumer and clinical use.
The company’s product pipeline includes novel CBD-infused nutraceuticals designed to promote general wellness, as well as specialized formulations for topical and inhalation delivery.
Further Reading
- Five stocks we like better than AXIM Biotechnologies
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for AXIM Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AXIM Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
